Engineering a Novel Antibody-peptide Bispecific Fusion Protein Against MERS-CoV

Simple item page
aut.relation.articlenumber53en_NZ
aut.relation.issue4en_NZ
aut.relation.journalAntibodiesen_NZ
aut.relation.volume8en_NZ
aut.researcherDrabsch, Julie
dc.contributor.authorWang, Len_NZ
dc.contributor.authorXu, Jen_NZ
dc.contributor.authorKong, Yen_NZ
dc.contributor.authorLiang, Ren_NZ
dc.contributor.authorLi, Wen_NZ
dc.contributor.authorLi, Jen_NZ
dc.contributor.authorLu, Jen_NZ
dc.contributor.authorDimitrov, DSen_NZ
dc.contributor.authorYu, Fen_NZ
dc.contributor.authorWu, Yen_NZ
dc.contributor.authorYing, Ten_NZ
dc.date.accessioned2020-06-28T23:46:31Z
dc.date.available2020-06-28T23:46:31Z
dc.date.copyright2019en_NZ
dc.date.issued2019en_NZ
dc.description.abstractIn recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct. However, to the best of our knowledge there has been no reported cases of effective antiviral antibody-peptide bispecific fusion proteins. We previously developed potent fully human monoclonal antibodies and inhibitory peptides against Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a novel coronavirus that causes severe acute respiratory illness with high mortality. Here, we describe the generation of antibody-peptide bispecific fusion proteins, each of which contains an anti-MERS-CoV single-chain antibody m336 (or normal human IgG1 CH3 domain as a control) linked with, or without, a MERS-CoV fusion inhibitory peptide HR2P. We found that one of these fusion proteins, designated as m336 diabody-pep, exhibited more potent inhibitory activity than the antibody or the peptide alone against pseudotyped MERS-CoV infection and MERS-CoV S protein-mediated cell-cell fusion, suggesting its potential to be developed as an effective bispecific immunotherapeutic for clinical use.en_NZ
dc.identifier.citationAntibodies 2019, 8(4), 53; https://doi.org/10.3390/antib8040053
dc.identifier.doi10.3390/antib8040053en_NZ
dc.identifier.issn2073-4468en_NZ
dc.identifier.urihttps://hdl.handle.net/10292/13463
dc.languageengen_NZ
dc.publisherMDPI AGen_NZ
dc.relation.urihttps://www.mdpi.com/2073-4468/8/4/53
dc.rightsThis is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.rights.accessrightsOpenAccessen_NZ
dc.subjectMERS-CoVen_NZ
dc.subjectBispecificen_NZ
dc.subjectImmunotherapeuticsen_NZ
dc.subjectmAbsen_NZ
dc.subjectPolypeptidesen_NZ
dc.titleEngineering a Novel Antibody-peptide Bispecific Fusion Protein Against MERS-CoVen_NZ
dc.typeJournal Article
pubs.elements-id365752
pubs.organisational-data/AUT
pubs.organisational-data/AUT/Health & Environmental Science
pubs.organisational-data/AUT/Health & Environmental Science/Interprofessional Health
pubs.organisational-data/AUT/PBRF
pubs.organisational-data/AUT/PBRF/PBRF Health and Environmental Sciences
pubs.organisational-data/AUT/PBRF/PBRF Health and Environmental Sciences/HI Interprofessional 2018 PBRF
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wang_2019_Engineering.pdf
Size:
1.64 MB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
AUT Grant of Licence for Tuwhera Aug 2018.pdf
Size:
276.29 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
School of Interprofessional Health Studies